| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Portage Biotech Inc. | IMM60 + Keytruda - (PORT-2) | PD-L1 Pos NSCLC Front line | Phase 2 | Clinical Pause | intravenous | Oncology |
| Praxis Precision Medicines Inc. | Relutrigine (PRAX-562) - (EMBOLD) | Developmental epileptic encephalopathies (DEEs) | NDA Filing | Data Released | Oral | Neurology |
| Praxis Precision Medicines Inc. | Relutrigine (PRAX-562) - (EMBOLD) | Developmental epileptic encephalopathies (DEEs) | NDA Filing | Data Released | Oral | Neurology |
| Praxis Precision Medicines Inc. | Ulixacaltamide ​(PRAX-944) - (Essential3) | Essential tremor | NDA Filing | Data Released | Oral | Neurology |
| Praxis Precision Medicines Inc. | PRAX-628 - (POWER1) | Epilepsy | Phase 2/3 | Enrollment Initiation | Oral | Neurology |
| Praxis Precision Medicines Inc. | PRAX-628 - (POWER2) | Epilepsy | Phase 2/3 | Trial Planned | Oral | Neurology |
| Praxis Precision Medicines Inc. | PRAX-114 - (Aria Study; Study 213) | Major Depressive Disorder | Phase 2/3 | oral | Psychiatric | |
| Praxis Precision Medicines Inc. | Elsunersen (PRAX-222) - (EMBRAVE) | Early-seizure-onset SCN2A developmental and epileptic encephalopathy (DEE) | Phase 2 | Data Released | Intrathecal | Neurology |